

Phase II clinical development of DPP-4 inhibitor (Evogliptin), a new drug for medical treatment of Aortic Stenosis



CARDIOVASCULAR	Phase 2
Product Type	Chemical Product
Indication	1st Indication : Calcific Aortic Valve Disease (CAVD)
Target	Dipeptidyl Peptidase-4 (DPP-4)
MoA (Mechanism of Action)	<p>DPP-4 – IGF-1 axis as a promising therapeutic target</p>
Competitiveness	First In Class. There is huge unmet medical need for CAVD worldwide, and the surgery (TAVR or SAVR) is the only option for now. Moreover, the Evogliptin showed the most decreased calcification by DPP-4 inhibition in an animal model of aortic valve calcification compared to other seven (7) DPP-4 inhibitors.
Development Stage	Phase II/III, US(NCT05143177); Phase II, KR(NCT04055883); Phase IV, KR(NCT04521452)
Route of Administration	Oral, QD